Matrix-M

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Matrix-M
DrugBank Accession Number
DB16369
Background

Matrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax.1 This compound is administered alongside vaccines to enhance biological functions: creating robust and long-lasting immune responses that may allow for dose-sparing of vaccines.

Type
Biotech
Groups
Investigational
Synonyms
  • Matrix-M1
  • Matrix-M1 Adjuvant
External IDs
  • Matrix-M

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Matrix-M can enhance activated T-cell, B-cell, and antigen-presenting cell populations by inducing the influx of antigen-presenting cells.1 It can also enhance both B-cell immunity and T-cell immunity.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
YZ7P8Y8ECX
CAS number
Not Available

References

General References
  1. Novavax: Novavax addresses urgent global public health needs with innovative technology [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingPreventionCoronavirus (SARS-CoV) / Coronavirus Disease 2019 (COVID‑19)1
3Enrolling by InvitationPreventionPlasmodium Infections1
2CompletedPreventionRespiratory Syncytial Virus (RSV)1
2Not Yet RecruitingTreatmentMalaria caused by Plasmodium falciparum1
2RecruitingPreventionCoronavirus Disease 2019 (COVID‑19)1
1CompletedPreventionEbola1
1CompletedPreventionMatrix M / Plasmodium Infections1
1CompletedPreventionPlasmodium Infections1
1Enrolling by InvitationPreventionMalaria caused by Plasmodium falciparum1
1RecruitingTreatmentMalaria caused by Plasmodium falciparum1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 20, 2020 03:30 / Updated on December 20, 2020 03:42